Los Angeles Capital Management LLC Decreases Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Los Angeles Capital Management LLC trimmed its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 42.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,946 shares of the medical equipment provider’s stock after selling 11,772 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Lantheus were worth $989,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Parkside Financial Bank & Trust boosted its position in Lantheus by 36.6% in the third quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 156 shares during the last quarter. Prosperity Financial Group Inc. lifted its stake in shares of Lantheus by 6.2% in the 3rd quarter. Prosperity Financial Group Inc. now owns 2,967 shares of the medical equipment provider’s stock worth $206,000 after purchasing an additional 173 shares during the period. Vanguard Personalized Indexing Management LLC grew its position in Lantheus by 3.1% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 6,217 shares of the medical equipment provider’s stock valued at $432,000 after buying an additional 188 shares during the period. Covestor Ltd increased its holdings in Lantheus by 62.7% during the third quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 203 shares during the last quarter. Finally, First Horizon Advisors Inc. increased its holdings in Lantheus by 97.0% during the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 225 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Stock Up 1.9 %

Shares of LNTH opened at $75.90 on Friday. The business’s 50 day moving average is $63.37 and its 200 day moving average is $62.97. The company has a current ratio of 4.84, a quick ratio of 4.55 and a debt-to-equity ratio of 0.59. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $100.85. The company has a market capitalization of $5.26 billion, a PE ratio of 11.59 and a beta of 0.52.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.26. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The firm had revenue of $354.00 million for the quarter, compared to analysts’ expectations of $350.44 million. Research analysts expect that Lantheus Holdings, Inc. will post 5.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Lantheus

In other news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The shares were acquired at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Insiders sold 94,545 shares of company stock valued at $6,169,936 in the last 90 days. Insiders own 2.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LNTH. Truist Financial boosted their price objective on shares of Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research report on Friday, May 3rd. JMP Securities restated a “market outperform” rating and issued a $100.00 price target on shares of Lantheus in a research report on Friday, February 23rd. B. Riley raised their price objective on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. Mizuho boosted their price objective on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. Finally, StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and an average price target of $99.17.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.